| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 306 | IT 7 | 99.10 |
| Treatment of Major Depression | Lifetime | 86 | IT 2 | 99.20 |
| Mental Health Treatment and Access | Lifetime | 135 | IT 2 | 99.25 |
| Schizophrenia research and treatment | Lifetime | 220 | IT 3 | 99.19 |
| Migration, Health and Trauma | Lifetime | 190 | IT 2 | 98.22 |
| Clinical practice guidelines implementation | Lifetime | 152 | IT 2 | 97.94 |
| Pharmaceutical studies and practices | Lifetime | 250 | IT 5 | 97.79 |
| Pharmaceutical Economics and Policy | Lifetime | 178 | IT 4 | 97.32 |
| Psychiatric care and mental health services | Lifetime | 123 | IT 4 | 97.83 |
| Electroconvulsive Therapy Studies | Lifetime | 110 | IT 4 | 98.04 |
| Bipolar Disorder and Treatment | Lifetime | 426 | IT 18 | 97.67 |
| COVID-19 and Mental Health | Lifetime | 800 | IT 62 | 95.02 |
| Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes | Lifetime | 626 | IT 7 | 96.77 |
| Meta-analysis and systematic reviews | Lifetime | 329 | IT 4 | 95.70 |
| Healthcare Decision-Making and Restraints | Lifetime | 300 | IT 2 | 94.51 |
| Health Policy Implementation Science | Lifetime | 625 | IT 4 | 95.10 |
| Mental Health and Psychiatry | Lifetime | 682 | IT 19 | 95.14 |
| Resilience and Mental Health | Lifetime | 982 | IT 16 | 92.94 |
| Pharmacovigilance and Adverse Drug Reactions | Lifetime | 294 | IT 14 | 92.39 |
| Posttraumatic Stress Disorder Research | Lifetime | 855 | IT 9 | 91.80 |
| Pharmaceutical industry and healthcare | Lifetime | 828 | IT 11 | 80.92 |
| Psychiatry, Mental Health, Neuroscience | Lifetime | 129 | IT 36 | 67.98 |
| Education and experiences of immigrants and refugees | Lifetime | 839 | IT 9 | 54.87 |
| Mental Health Treatment and Access | 2021-2025 | 33 | IT 1 | 98.86 |
| Migration, Health and Trauma | 2021-2025 | 128 | IT 4 | 96.08 |
| COVID-19 and Mental Health | 2021-2025 | 545 | IT 40 | 95.45 |
| Child and Adolescent Psychosocial and Emotional Development | 2021-2025 | 786 | IT 21 | 92.99 |
| Schizophrenia research and treatment | 2021-2025 | 444 | IT 45 | 92.44 |
| Pharmaceutical studies and practices | 2021-2025 | 454 | IT 28 | 83.29 |
| Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes | 2021-2025 | 721 | IT 47 | 83.38 |
| Pharmaceutical Economics and Policy | 2021-2025 | 469 | IT 21 | 81.39 |
| Resilience and Mental Health | 2021-2025 | 934 | IT 34 | 79.63 |
| Bipolar Disorder and Treatment | 2021-2025 | 981 | IT 117 | 79.12 |
| Posttraumatic Stress Disorder Research | 2021-2025 | 640 | IT 11 | 78.65 |
| Treatment of Major Depression | 2021-2025 | 832 | IT 57 | 76.34 |
| Pharmacovigilance and Adverse Drug Reactions | 2021-2025 | 359 | IT 24 | 70.99 |
| Healthcare Decision-Making and Restraints | 2021-2025 | 572 | IT 17 | 65.46 |
| Education and experiences of immigrants and refugees | 2021-2025 | 294 | IT 5 | 49.17 |
| Health and Conflict Studies | 2021-2025 | 746 | IT 19 | 35.49 |
